Pelabresib for primary myelofibrosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Oct 2020: Trial registered, NCT04603495
  2. 9 Apr 2021: Trial started, NCT04603495

The trials

NCT04603495: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

State
Under way
Phase
Phase 3
People
430 taking part
Started
9 Apr 2021
Primary completion
23 Aug 2023
Arms
Pelabresib + ruxolitinib
Results
Posted on the registry
  1. 26 Oct 2020: Trial registered
  2. 9 Apr 2021: Trial started
  3. 28 Oct 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.